-+ 0.00%
-+ 0.00%
-+ 0.00%

DOGWOOD THERAPEUTICS ANNOUNCES 50% ENROLLMENT IN ONGOING HALNEURON® PHASE 2B TRIAL, TOP LINE RESULTS ANTICIPATED IN Q3 2026

Reuters·02/02/2026 13:30:02

Please log in to view news